Keros Therapeutics, Inc. — Form 8-K Summary
Reporting date: September 28, 2026. This current report concerns a clinical-development update, not a periodic financial-results report.
Business context and material event
Keros announced that the first patient was dosed in its Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy. The 8-K identifies the press release as Exhibit 99.1, but its text is not included in the provided filing content.
Financial information and comparison
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It provides no comparable-period financial information.
Outlook, risks, and contingencies
No guidance, detailed outlook, trial results, or specific risks or contingencies are stated in the provided text. The first-patient dosing announcement does not report clinical efficacy or safety findings.
The information is furnished under Item 7.01 and is not deemed filed for purposes of Exchange Act Section 18, except as otherwise expressly provided.
Investor verification points
- Review Exhibit 99.1 for the trial design, planned enrollment, endpoints, timing, and any additional management commentary.
- Monitor subsequent disclosures for trial progress and safety or efficacy results.
- Consult Keros’s periodic filings for financial position, cash runway, and liquidity information; this 8-K does not provide those details.